Colorectal cancer (CRC) is a leading global health burden, ranking as the third most common malignancy and the second most deadly cancer worldwide. While bacterial dysbiosis in the gut has long been ...

First-in-class solution consolidates multiple assays into a single test, enabling broader viral detection, faster time-to-result and more confident decision-making in regulated biopharmaceutical ...

Inherently vulnerable to viral contamination, biologics rely on animal- or human-derived starting materials and complex manufacturing processes. Albeit rare, viral contamination incidents are ...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...

Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...

Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...

We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...

BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...

The MarketWatch News Department was not involved in the creation of this content. First-in-class solution consolidates multiple assays into a single test, enabling broader viral detection, faster time ...